Retreatment with bevacizumab in patients with gynecologic malignancy is associated with clinical response and does not increase morbidity.
暂无分享,去创建一个
T. Krivak | J. Kelley | R. Laskey | Ashlee L. Smith | A. Olawaiye | S. Richard | P. Sukumvanich | Jeff F. Lin | T. Beck | J. Lesnock